Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments

Differential Expression and Molecular Associations of Syk in Systemic Lupus Erythematosus T Cells

(2014) S. Krishnan et al.   JOURNAL OF IMMUNOLOGY

Suppression of Glomerulonephritis in Lupus-Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase

(2013) Paola Mina-Osorio et al.   ARTHRITIS AND RHEUMATISM

MicroRNA-30a Promotes B Cell Hyperactivity in Patients With Systemic Lupus Erythematosus by Direct Interaction With Lyn

(2013) Yu Liu et al.   ARTHRITIS AND RHEUMATISM

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

(2013) Amin Aalipour et al.   BRITISH JOURNAL OF HAEMATOLOGY

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

(2013) David G. Winkler et al.   CHEMISTRY & BIOLOGY

B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress

(2013) Md Yuzaiful Md Yusof et al.   Expert Review of Clinical Immunology

Genetic susceptibility to SLE: Recent progress from GWAS

(2013) Yong Cui et al.   JOURNAL OF AUTOIMMUNITY

Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis

(2013) A. L. Rankin et al.   JOURNAL OF IMMUNOLOGY

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

(2013) Cheng Liao et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

(2012) A. Wiestner   BLOOD

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice

(2012) L. P. Kil et al.   BLOOD

Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease

(2012) Mhairi J. Maxwell et al.   JOURNAL OF AUTOIMMUNITY

TLRs and IFNs: critical pieces of the autoimmunity puzzle

(2012) Argyrios N. Theofilopoulos   JOURNAL OF CLINICAL INVESTIGATION

Colonel Bruton's Kinase Defined the Molecular Basis of X-Linked Agammaglobulinemia, the First Primary Immunodeficiency

(2012) W. N. Khan   JOURNAL OF IMMUNOLOGY

Genetic Interdependence of Lyn and Negative Regulators of B Cell Receptor Signaling in Autoimmune Disease Development

(2012) E. Tsantikos et al.   JOURNAL OF IMMUNOLOGY

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

(2012) Jack Hutcheson et al.   ARTHRITIS RESEARCH & THERAPY

Enhanced Phosphoinositide 3-Kinase   Activity Is a Frequent Event in Systemic Lupus Erythematosus That Confers Resistance to Activation-Induced T Cell Death

(2011) A. Suarez-Fueyo et al.   JOURNAL OF IMMUNOLOGY

IRF4 Deficiency Abrogates Lupus Nephritis Despite Enhancing Systemic Cytokine Production

(2011) M. Lech et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Systemic Lupus Erythematosus

(2011) George C. Tsokos   NEW ENGLAND JOURNAL OF MEDICINE

Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases

(2011) Omer N Pamuk et al.   ARTHRITIS RESEARCH & THERAPY

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

(2010) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

(2010) Michael E. Weinblatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Genetic associations of LYN with systemic lupus erythematosus

(2009) R Lu et al.   GENES AND IMMUNITY

Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

(2009) Abdalla J. Mohamed et al.   IMMUNOLOGICAL REVIEWS

B Cell Receptor and BAFF Receptor Signaling Regulation of B Cell Homeostasis

(2009) W. N. Khan   JOURNAL OF IMMUNOLOGY

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial

(2008) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

(2008) Frances Rena Bahjat et al.   ARTHRITIS AND RHEUMATISM

Altered B-cell signaling in lupus

(2008) Kui Liu et al.   AUTOIMMUNITY REVIEWS